Companies / Autolus Therapeutics plc

Autolus Therapeutics plc

Nasdaq: AUTLForeign · IFRSCIK 1730463LONDON

Financials · FY2025

Revenue$75.39M
Net income$-287.53M
Total debt$0
Cash$171.41M
Diluted EPS$-1.08
Shares outstanding266.2M

Ownership

266.2M shares outstanding · as of Aug 10, 2026
17.8%10%+ / strategic
Ownership
10%+ / strategic17.85%47,505,343
Institutions46.43%123,585,644
Public float35.72%95,071,553

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 21

View all →
Insider% of sharesShares
Bain LindaDirector
Dolski RobertChief Financial Officer
Driggs AlexSVP, Legal Affairs and GC
Itin ChristianCEOChief Executive Officer · Director

Institutional holders 93

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
No activity matches these filters.

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
MAK Capital Fund LPPassive13G/A30,005,343
Armistice Capital, LLCPassive13G/A17,500,000

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AUTLADREquity05280R100BBG00KVT05R6